Investigators electrify antibiotic R&D field with claims of a breakthrough

Antibiotic R&D fell out of favor at Big Pharma companies years ago, chilling a field that only recently has shown signs of heating up with new development projects. But a transatlantic team of investigators electrified the field this week with its claims that a new antibiotic found in dirt was a potent killer of drug-resistant bacteria. And it could represent a new class of badly needed antibiotics that just might avoid the natural resistance that begins to evolve once a new antibiotic hits the market.

The antibiotic, dubbed teixobactin, works by stopping microbes from building cell walls, rather than targeting proteins--an approach that inevitably leads bacteria to develop new proteins that can escape antibiotics. And in mice, at least, it proved a potent antidote to Staphylococcus aureus, Streptococcus pneumoniae and Enterococcus.

"Teixobactin inhibits cell wall synthesis by binding to a highly conserved motif of lipid II (precursor of peptidoglycan) and lipid III (precursor of cell wall teichoic acid)," the researchers reported in Nature. "We did not obtain any mutants of Staphylococcus aureus or Mycobacterium tuberculosis resistant to teixobactin. The properties of this compound suggest a path towards developing antibiotics that are likely to avoid development of resistance."

There are limitations. This new antibiotic only works against gram-positive bacteria, not gram-negative. And while the news of the advance spawned headlines around the world as public health officials grapple with the threat of drug-resistant bacteria, the work has to be carried forward into humans to prove its potential.

"What most excites me is the tantalising prospect that this discovery is just the tip of the iceberg," University of Edinburgh Professor Mark Woolhouse tells The Guardian. "It may be that we will find more, perhaps many more, antibiotics using these latest techniques."

- here's the link to Nature
- here's the report in The Guardian

Suggested Articles

Antibiotics dubbed odilorhabdins (ODLs), inspired by soil-dwelling nematodes, hold promise for treating antibiotic-resistant infections.

A PureTech startup is developing an immune-responsive hydrogel that releases a corticosteroid into arthritic joints based on their level of inflammation.

A trial of a retinal implant built from embryonic stem cells produced encouraging results in patients with dry age-related macular degeneration.